Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML

Sponsor

University of Kentucky (Other)

Overall Status

Completed

CT.gov ID

NCT00382954

Collaborator

National Institutes of Health (NIH) (NIH)

Enrollment

Locations

Arm

Duration (Months)

27.5

Patients Per Site

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the maximal tolerated dose (MTD) of bortezomib and idarubicin given in combination to newly diagnosed AML patients >60 years or relapsed AML patients.

Another purpose of this study is to determine the dose limiting toxicities associated with bortezomib in combination with idarubicin in newly diagnosed AML patients >60 years or relapsed AML patients.

Condition or Disease	Intervention/Treatment	Phase
Acute Myelogenous Leukemia	Drug: Velcade Drug: Idarubicin	Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

55 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase I Study Using Bortezomib (Velcade, Formerly Known as PS-341) With Weekly Idarubicin for the Treatment of Elderly (>/= 60 Years) and Relapsed Patients With Acute Myelogenous Leukemia

Study Start Date :

Feb 1, 2004

Actual Primary Completion Date :

Oct 1, 2008

Actual Study Completion Date :

Oct 1, 2008

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Phase 1 escalation	Drug: Velcade velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin Other Names: Bortezomib Drug: Idarubicin I.V., 8, or 10 or 12 mg/m^2 weekly (days 1, 8, 15, and 22) for 4 weeks

Arm

Intervention/Treatment

Experimental: Phase 1 escalation

Drug: Velcade

velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin

Other Names:

Bortezomib

Drug: Idarubicin

I.V., 8, or 10 or 12 mg/m^2 weekly (days 1, 8, 15, and 22) for 4 weeks

Outcome Measures

Primary Outcome Measures

Maximum tolerated dose of bortezomib & idarubicin given in combination, with idarubicin given once weekly for 4 consecutive weeks & bortezomib given twice weekly over the same time. [week 4]
Dose limiting toxicities associated with bortezomib in combination with idarubicin. [week 4]

Secondary Outcome Measures

Response to the combination of Idarubicin and Bortezomib. [Days 18 & 50]
Pre- & post-treatment inhibition of NF-kB activity in the malignant & normal hematopoietic cell populations. [24 hours after the initial dose of Bortezomib]
Induction of p53 levels in the malignant cell populations. [2 and 24 hours post day +1 Bortezomib]
Bortezomib PK when administered to patients with acute leukemia receiving concomitant medications that could lead to drug interactions. In the case of altered pharmacokinetics, a pharmacodynamic assay to check proteasome inhibition may also be applied. [Days 1, 4, 8, 11, 15]
Idarubicin PK in order to observe any alteration in metabolism/elimination of Idarubicin & its active metabolite idarubicinol when it is combined with Bortezomib. [Days 1, 4, 8, 11, 15]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age: > 60 years of age for newly diagnosed/transformed disease; > 18 years of age for relapsed disease.
AML with or without antecedent hematologic disorder diagnosed by morphologic, histochemical, or cell surface marker criteria - as defined by the WHO classification (17).
Newly diagnosed, elderly patients who are considered unsuitable for intensive chemotherapy induction -- antecedent hematologic disorders, pre-existing myelodysplasia, trilineage dyspoiesis, unfavorable cytogenetics, or pre-existing comorbidities.
Untreated conditions meeting criteria the first and third criteria or patients with diagnosis as in criteria 2 who have relapsed after at least one successful induction therapy. (Relapsed patients treated on this protocol will be patients without a suitable donor for transplant or for whom transplant is not an option for other reasons.)
Karnofsky performance status >60.
Adequate cardiac function as evidenced by an ejection fraction on MUGA >/= 40, as well as no evidence of uncontrolled hypertension, New York Heart Class III/IV congestive heart failure, angina pectoris, or ventricular dysrhythmias.
Adequate renal function as evidenced by a calculated creatinine clearance >/= 30ml/min (Cockcroft-Gault formula).
Adequate pulmonary function as evidenced by room air and exercise saturations >/= 92 or DLCO >/= 40% or FEV1 >/= 60% of predicted.
Adequate liver function as evidenced by SGOT/SGPT less than 5 times the ULN and total Bilirubin less than 2 times the ULN except where abnormalities are directly attributable to leukemia.
Adequate neurologic function -- patients must be currently free of active CNS leukemia as evidenced by cytospin of CSF from lumbar puncture if there is any clinical suspicion for CNS leukemia. As well, patients must not have >/= grade 2 neuropathy by NCI common toxicity criteria (CTC), Version 3.0.
Prior anthracycline dose in relapsed patients must not exceed 72 mg/m^{2 of idarubicin
or any dose equivalent to 300 mg/m}2 of adriamycin.
Patients must be informed and sign a written consent.

Exclusion Criteria:

Patients with acute promyelocytic leukemia. Patients with uncontrolled systemic infection.
Patients who are known to be HIV seropositive.
Patients with evidence of CNS leukemia.
Patients who are pregnant or lactating.
Patients with primarily refractory disease unresponsive to a standard induction regimen.
Patients with a new diagnosis as per inclusion criteria 2, but for whom standard induction chemotherapy would be expected to be well tolerated and a preferred option in the opinion of the principal investigator.
Patients with relapsed AML, but for whom a suitable donor of stem cells exists and in whom high-dose chemotherapy with hematopoietic stem cell transplant is felt to be a better immediate alternative.
Patients with any clinically significant abnormality in screening blood chemistry, hematology or urinalysis results that, in the judgment of the investigator, would impede adequate evaluation of adverse events and/or response to treatment, or that requires aggressive intervention.
Patients with hypersensitivity to Bortezomib, boron, or mannitol.